…atrophy in lateral C3-C4 regions was predictive of clinical disability at 1-year follow-up. Conclusions Cord atrophy was clinically relevant and contributed to disability at 1-year follow-up. Poster 170 – Clinical Characteristics and Disease Burden of African, Caribbean, and Black People with Multiple Sclerosis in Toronto, Canada Andrea Kuczynski, MD, PhD Objective: Compare disease characteristics in MS patients who are African/Caribbean/Black (AC…
…(NfL) A post-hoc analysis of CIS patients in the REFLEX trial of interferon-β-1a demonstrated that high baseline serum NfL levels were prognostic of conversion to clinically-definite MS (Kuhle J. AAN 2021; P.001). High vs. low NfL was defined by a median sNfL concentration cut-off of 26.1 pg/mL. Patients with lower sNfL had a 42% reduced risk of CDMS compared to those with higher baseline values. Serum NfL was elevated in 17% of MS patients in the…
…uous inebilizumab group and 83.4% of placebo/inebilizumab group were attack-free for up to 4 years. At week 78, EDSS scores had declined from OLP baseline in both groups (-0.24 and -0.12, respectively). Conclusions: The benefits of inebilizumab in NMOSD were maintained in the OLP. Poster 090 – Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis Tomas Kalincik, MD Objective: Assess if response to diseas…
…S28.002). The risk of ICU admission/death was somewhat higher for the anti-CD20 group (8%) compared to patients treated with an interferon-β (0%) or another DMT (5%). MS patients were also less likely to have asymptomatic COVID while on an anti-CD20 agent (1.1%) compared to an interferon (8.3%) or another DMT (4%). Risk factors for severe COVID were age (odds ratio 1.05), EDSS score (OR 1.13), male sex (OR 1.44) and DMT used (OR 1.99 for anti-CD2…
…Multiple Sclerosis (NARCRMS) Kottil W. Rammohan, MD Objective: 9-hole peg test (9-HPT) and 25-foot walk (25-FW) function. Data source: North American Registry for Care and Research in MS (NARCRMS) (N=777). Results: Mean walking speed (n=651): 4.96 sec at EDSS 0; 18.09 seconds at EDSS 6.5. Mean 9-HPT (n=647): 19.45 seconds (dominant hand) and 20.46 seconds (non-dominant hand) at EDSS 0; 38.43 seconds (dominant) and 50.88 seconds (non-dominant) at…